• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胆管癌的新型分子与免疫治疗方法

New molecular and immunotherapeutic approaches in biliary cancer.

作者信息

Goldstein David, Lemech Charlotte, Valle Juan

机构信息

Department of Medical Oncology at the Nelune Cancer Centre, Prince of Wales Hospital, Sydney, New South Wales, Australia; Prince of Wales Clinical School, University of New South Wales, Sydney, New South Wales, Australia.

Department of Medical Oncology at the Nelune Cancer Centre, Prince of Wales Hospital, Sydney, New South Wales, Australia; Prince of Wales Clinical School, University of New South Wales, Sydney, New South Wales, Australia.

出版信息

ESMO Open. 2017 Mar 27;2(Suppl 1):e000152. doi: 10.1136/esmoopen-2016-000152. eCollection 2017.

DOI:10.1136/esmoopen-2016-000152
PMID:28848675
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5559907/
Abstract

Biliary tract carcinoma is a collective term for a group of rare gastrointestinal cancers. This overview outlines the key pathways and specialised therapeutics in biliary cancer and the emerging role of immunotherapy by highlighting the rationale and selected examples of studies in each area.

摘要

胆管癌是一组罕见的胃肠道癌症的统称。本综述通过强调每个领域的研究原理和选定实例,概述了胆管癌的关键途径、专门治疗方法以及免疫疗法的新兴作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a8dd/5559907/cc982178d84d/esmoopen-2016-000152f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a8dd/5559907/cc982178d84d/esmoopen-2016-000152f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a8dd/5559907/cc982178d84d/esmoopen-2016-000152f01.jpg

相似文献

1
New molecular and immunotherapeutic approaches in biliary cancer.胆管癌的新型分子与免疫治疗方法
ESMO Open. 2017 Mar 27;2(Suppl 1):e000152. doi: 10.1136/esmoopen-2016-000152. eCollection 2017.
2
Immunotherapeutic approaches in biliary tract carcinoma: Current status and emerging strategies.胆管癌的免疫治疗方法:现状与新兴策略
World J Gastrointest Oncol. 2015 Nov 15;7(11):338-46. doi: 10.4251/wjgo.v7.i11.338.
3
Immunotherapeutic Approaches to Biliary Cancer.胆管癌的免疫治疗方法
Curr Treat Options Oncol. 2017 Jul;18(7):44. doi: 10.1007/s11864-017-0486-9.
4
Biomarker-Driven and Molecular Targeted Therapies for Hepatobiliary Cancers.肝胆肿瘤的生物标志物驱动和分子靶向治疗。
Semin Oncol. 2018 Jun;45(3):116-123. doi: 10.1053/j.seminoncol.2018.03.002. Epub 2018 Mar 16.
5
Immunotherapy of biliary tract cancer.胆管癌的免疫治疗
Tumour Biol. 2016 Mar;37(3):2817-21. doi: 10.1007/s13277-015-4743-x. Epub 2016 Jan 4.
6
The case for immune-based approaches in biliary tract carcinoma.基于免疫疗法治疗胆管癌的理由。
Hepatology. 2016 Nov;64(5):1785-1791. doi: 10.1002/hep.28635. Epub 2016 Jun 18.
7
The role of novel biologics in biliary cancers.新型生物制剂在胆管癌中的作用。
Minerva Gastroenterol Dietol. 2016 Dec;62(4):325-339. Epub 2016 Aug 31.
8
Systemic therapy for biliary cancers.胆管癌的全身治疗
Chin Clin Oncol. 2016 Oct;5(5):65. doi: 10.21037/cco.2016.10.08.
9
Immunotherapy as a treatment for biliary tract cancers: A review of approaches with an eye to the future.免疫疗法作为胆管癌的一种治疗方法:着眼未来的方法综述。
Curr Probl Cancer. 2018 Jan-Feb;42(1):49-58. doi: 10.1016/j.currproblcancer.2017.10.004. Epub 2017 Oct 31.
10
Cancer vaccines and immunotherapeutic approaches in hepatobiliary and pancreatic cancers.肝胆胰肿瘤的癌症疫苗和免疫治疗方法。
Hum Vaccin Immunother. 2017 Dec 2;13(12):2931-2952. doi: 10.1080/21645515.2017.1359362. Epub 2017 Nov 7.

引用本文的文献

1
Transforming pancreaticobiliary cancer treatment: Exploring the frontiers of adoptive cell therapy and cancer vaccines.变革胰胆管癌治疗:探索过继性细胞疗法和癌症疫苗的前沿领域。
Mol Ther Oncol. 2024 Jun 8;32(3):200825. doi: 10.1016/j.omton.2024.200825. eCollection 2024 Sep 19.
2
Tumor immune microenvironment and the current immunotherapy of cholangiocarcinoma (Review).肿瘤免疫微环境与胆管癌的当前免疫治疗(综述)。
Int J Oncol. 2023 Dec;63(6). doi: 10.3892/ijo.2023.5585. Epub 2023 Oct 27.
3
Optimizing Patient Pathways in Advanced Biliary Tract Cancers: Recent Advances and a French Perspective.

本文引用的文献

1
A Multicenter Phase II Study of Gemcitabine, Capecitabine, and Bevacizumab for Locally Advanced or Metastatic Biliary Tract Cancer.吉西他滨、卡培他滨和贝伐单抗治疗局部晚期或转移性胆管癌的多中心II期研究
Am J Clin Oncol. 2018 Jul;41(7):649-655. doi: 10.1097/COC.0000000000000347.
2
Systemic therapy for biliary cancers.胆管癌的全身治疗
Chin Clin Oncol. 2016 Oct;5(5):65. doi: 10.21037/cco.2016.10.08.
3
Biliary tract cancers: epidemiology, molecular pathogenesis and genetic risk associations.胆道癌:流行病学、分子发病机制及遗传风险关联
优化胆道晚期癌症患者的治疗路径:最新进展和法国视角。
Target Oncol. 2023 Jan;18(1):51-76. doi: 10.1007/s11523-022-00942-6. Epub 2023 Feb 6.
4
Gallbladder Cancer: Current Multimodality Treatment Concepts and Future Directions.胆囊癌:当前的多模态治疗理念与未来方向
Cancers (Basel). 2022 Nov 14;14(22):5580. doi: 10.3390/cancers14225580.
5
The Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Based on FOLFIRI for Advanced Intrahepatic Cholangiocarcinoma as Second-Line and Successive Treatment: A Real-World Study.基于 FOLFIRI 的肝动脉灌注化疗治疗晚期肝内胆管细胞癌二线及序贯治疗的疗效和安全性:一项真实世界研究。
Can J Gastroenterol Hepatol. 2022 Sep 26;2022:9680933. doi: 10.1155/2022/9680933. eCollection 2022.
6
Cholangiocarcinoma: the quest for a second-line systemic treatment.胆管癌:二线全身治疗的探索
Transl Cancer Res. 2019 Apr;8(Suppl 3):S275-S288. doi: 10.21037/tcr.2018.10.05.
7
Mutational landscape of paired primary and synchronous metastatic lymph node in chemotherapy naive gallbladder cancer.化疗初治胆囊癌配对原发灶和同步转移淋巴结的突变全景。
Mol Biol Rep. 2022 Feb;49(2):1295-1301. doi: 10.1007/s11033-021-06957-y. Epub 2022 Jan 5.
8
Optimal Management of Patients with Advanced or Metastatic Cholangiocarcinoma: An Evidence-Based Review.晚期或转移性胆管癌患者的最佳管理:一项基于证据的综述。
Cancer Manag Res. 2021 Oct 27;13:8085-8098. doi: 10.2147/CMAR.S276104. eCollection 2021.
9
Targeting P53 as a Future Strategy to Overcome Gemcitabine Resistance in Biliary Tract Cancers.以 P53 为靶点,探索克服胆管癌中吉西他滨耐药的新策略。
Biomolecules. 2020 Oct 23;10(11):1474. doi: 10.3390/biom10111474.
10
Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies.克服胃肠道恶性肿瘤对抗 PD-1 和抗 PD-L1 治疗的耐药性。
J Immunother Cancer. 2020 May;8(1). doi: 10.1136/jitc-2019-000404.
Chin Clin Oncol. 2016 Oct;5(5):61. doi: 10.21037/cco.2016.10.09.
4
Molecular profiling of biliary tract cancer: a target rich disease.胆管癌的分子图谱:一个靶点丰富的疾病。
J Gastrointest Oncol. 2016 Oct;7(5):797-803. doi: 10.21037/jgo.2016.09.01.
5
Biliary cancer: Utility of next-generation sequencing for clinical management.胆管癌:新一代测序在临床管理中的应用
Cancer. 2016 Dec 15;122(24):3838-3847. doi: 10.1002/cncr.30254. Epub 2016 Sep 13.
6
Current Progress in Immunotherapy for the Treatment of Biliary Cancers.胆管癌免疫治疗的当前进展
J Gastrointest Cancer. 2016 Dec;47(4):351-357. doi: 10.1007/s12029-016-9867-8.
7
Targeting isocitrate dehydrogenase (IDH) in cancer.在癌症中靶向异柠檬酸脱氢酶(IDH)。
Discov Med. 2016 May;21(117):373-80.
8
Biliary Tract Cancer: Epidemiology, Radiotherapy, and Molecular Profiling.胆道癌:流行病学、放射治疗及分子特征分析
Am Soc Clin Oncol Educ Book. 2016;35:e194-203. doi: 10.1200/EDBK_160831.
9
The case for immune-based approaches in biliary tract carcinoma.基于免疫疗法治疗胆管癌的理由。
Hepatology. 2016 Nov;64(5):1785-1791. doi: 10.1002/hep.28635. Epub 2016 Jun 18.
10
The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets.胆管癌靶向治疗的现状与新兴靶点
Oncotarget. 2016 Jul 19;7(29):46750-46767. doi: 10.18632/oncotarget.8775.